TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

Abroad (travel likely)RecruitingPHASE4

Conditions

Crohn Disease (CD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Wei Wang, MD) · wangw239@mail.sysu.edu.cn · 86-18702046420

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

Inflamatory Bowel Disease · Crohn Disease (CD)

Abroad (travel likely)Recruiting

Shanghai, China

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)RecruitingPHASE4

Montreal, Canada

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Inflammatory Bowel Disease (IBD) · Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)Recruiting

Calgary, Canada · Fredericton, Canada

IBD Biomarker Discovery and Validation Platform

Crohn Disease (CD) · Ulcerative Colitis (UC) · Inflammatory Bowel Diseases (IBD)

Abroad (travel likely)Recruiting

Guangzhou, China · Guangzhou, China